LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Stock List・Kura Oncology Inc

Kura Oncology Inc

Closed

SectorHealthcare

8.74 -0.91

Buy Sell

Overview

Share price change

24h

Current

Min

8.69

Max

9.1

Key metrics
By Trading Economics
Income	7.7M -73M
Sales	929K 18M
EPS	-0.828
Profit margin	-401.495
Employees	260
EBITDA	7.4M -78M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+219.07% upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-84M 760M
Previous open	9.65
Previous close	8.74

News Sentiment

By Acuity

100%

315 / 344 Healthcare

Kura Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Jun 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 Jun 2026, 23:45 UTC

Acquisitions, Mergers, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 Jun 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 Jun 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 Jun 2026, 23:43 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 Jun 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 Jun 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 Jun 2026, 20:51 UTC

Earnings

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jun 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Jun 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 Jun 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 Jun 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 Jun 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 Jun 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 Jun 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 Jun 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 Jun 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 Jun 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 Jun 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 Jun 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 Jun 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 Jun 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 Jun 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

219.07% upside

12 Months Forecast

Average 28.11 USD 219.07%

High 40 USD

Low 15 USD

Based on 10 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Kura Oncology Inc - Dist in the past 3 months.

Sentiment

By Acuity

315 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.